24 April 2017
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
In accordance with article 19(1) of the Market Abuse Regulations, the Company was notified today that due to a change in personal circumstances Ian Page's total beneficial interest in the Company is now 811,308 shares, which represents 0.871% of the current issued share capital.
The reduction in his beneficial shareholding relates to shares held by his sons, Andrew, David and Michael Page, who are no longer classified as a connected person under the Market Abuse Regulations.
The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
Notification of Dealing Form
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") |
||
a) |
Name |
Ian Page
|
|
2. |
Reason for the notification |
||
a) |
Position/status |
Director
|
|
b) |
Initial notification/ amendment |
Initial Notification |
|
3. |
Details of the Issuer |
||
a) |
Name |
Dechra Pharmaceuticals PLC |
|
b) |
LEI code |
N/A |
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 1 pence each
ISIN: GB0009633180 |
|
b) |
Nature of the transaction |
Shares held by sons, who are no longer connected people |
|
c) |
Price(s) and volumes(s) |
Price(s) Nil cost Nil cost Nil cost |
Volume(s) 2,600 2,000 2,000 |
d) |
Aggregated information - Aggregate volume - Price |
6,600
Nil cost |
|
e) |
Date of the transaction |
2017.04.24 |
|
f) |
Place of the transaction |
Outside a trading venue |
For further information, please contact:
Suzana Cross, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.